Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip
- PMID: 19913121
- PMCID: PMC2775832
- DOI: 10.1016/j.ajhg.2009.10.014
Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip
Abstract
Blood lipids are important cardiovascular disease (CVD) risk factors with both genetic and environmental determinants. The Whitehall II study (n=5592) was genotyped with the gene-centric HumanCVD BeadChip (Illumina). We identified 195 SNPs in 16 genes/regions associated with 3 major lipid fractions and 2 apolipoprotein components at p<10(-5), with the associations being broadly concordant with prior genome-wide analysis. SNPs associated with LDL cholesterol and apolipoprotein B were located in LDLR, PCSK9, APOB, CELSR2, HMGCR, CETP, the TOMM40-APOE-C1-C2-C4 cluster, and the APOA5-A4-C3-A1 cluster; SNPs associated with HDL cholesterol and apolipoprotein AI were in CETP, LPL, LIPC, APOA5-A4-C3-A1, and ABCA1; and SNPs associated with triglycerides in GCKR, BAZ1B, MLXIPL, LPL, and APOA5-A4-C3-A1. For 48 SNPs in previously unreported loci that were significant at p<10(-4) in Whitehall II, in silico analysis including the British Women's Heart and Health Study, BRIGHT, ASCOT, and NORDIL studies (total n>12,500) revealed previously unreported associations of SH2B3 (p<2.2x10(-6)), BMPR2 (p<2.3x10(-7)), BCL3/PVRL2 (flanking APOE; p<4.4x10(-8)), and SMARCA4 (flanking LDLR; p<2.5x10(-7)) with LDL cholesterol. Common alleles in these genes explained 6.1%-14.7% of the variance in the five lipid-related traits, and individuals at opposite tails of the additive allele score exhibited substantial differences in trait levels (e.g., >1 mmol/L in LDL cholesterol [approximately 1 SD of the trait distribution]). These data suggest that multiple common alleles of small effect can make important contributions to individual differences in blood lipids potentially relevant to the assessment of CVD risk. These genes provide further insights into lipid metabolism and the likely effects of modifying the encoded targets therapeutically.
Figures
References
-
- Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., McInnes G.T., Mehlsen J. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J. Hypertens. 2001;19:1139–1147. - PubMed
-
- Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O., Lanke J., de Faire U., Dahlof B., Karlberg B.E. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–365. - PubMed
-
- Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–315. - PubMed
-
- Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847. - PubMed
-
- Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- G9521010/MRC_/Medical Research Council/United Kingdom
- RG/08/008/25291/BHF_/British Heart Foundation/United Kingdom
- 33014/PHS HHS/United States
- G19/35/MRC_/Medical Research Council/United Kingdom
- SP/08/005/25115/BHF_/British Heart Foundation/United Kingdom
- G0100222/MRC_/Medical Research Council/United Kingdom
- SP/07/007/23671/BHF_/British Heart Foundation/United Kingdom
- R37 AG013196/AG/NIA NIH HHS/United States
- RG/08/008/BHF_/British Heart Foundation/United Kingdom
- RG/07/005/23633/BHF_/British Heart Foundation/United Kingdom
- R01 AG013196/AG/NIA NIH HHS/United States
- HS06516/HS/AHRQ HHS/United States
- PG/07/133/24260/BHF_/British Heart Foundation/United Kingdom
- RG/07/008/23674/BHF_/British Heart Foundation/United Kingdom
- R01 HL036310/HL/NHLBI NIH HHS/United States
- G0600705/MRC_/Medical Research Council/United Kingdom
- PG/07/131/24254/BHF_/British Heart Foundation/United Kingdom
- AG13196/AG/NIA NIH HHS/United States
- DH_/Department of Health/United Kingdom
- FS/05/065/19497/BHF_/British Heart Foundation/United Kingdom
- G8802774/MRC_/Medical Research Council/United Kingdom
- PG/02/128/BHF_/British Heart Foundation/United Kingdom
- FS/2005/125/BHF_/British Heart Foundation/United Kingdom
- G9521010D/MRC_/Medical Research Council/United Kingdom
- HL36310/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
